News | December 30, 2022
Cipla EU to invest € 15 million in Ethris
Cipla and Ethris partner for the development of mRNA-based therapies
Cipla and Ethris partner for the development of mRNA-based therapies
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
Strengthens investment in channels of the future to expand patient reach
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Subscribe To Our Newsletter & Stay Updated
